OBJECTIVES: Prostate cancer mortality (PCM) in the USA is among the lowest in the world, whereas PCM in England is among the highest in Europe.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
This paper aims to assess the association of variation in use of definitive therapy on risk-adjusted PCM in England as compared with the USA.
DESIGN: Observational study.
SETTING: Cancer registry data from England and the USA.
PARTICIPANTS: Men diagnosed with non-metastatic prostate cancer (PCa) in England and the USA between 2004 and 2008.
OUTCOME MEASURES: Competing-risks survival analyses to estimate subhazard ratios (SHR) of PCM adjusted for age, ethnicity, year of diagnosis, Gleason score (GS) and clinical tumour (cT) stage.
RESULTS: 222,163 men were eligible for inclusion. Compared with American patients, English patients were more likely to present at an older age (70-79 years: England 44.2%, USA 29.3%, p< 0.001), with higher tumour stage (cT3-T4: England 25.1%, USA 8.6%, p< 0.001) and higher GS (GS 8-10: England 20.7%, USA 11.2%, p< 0.001). They were also less likely to receive definitive therapy (England 38%, USA 77%, p< 0.001). English patients were more likely to die of PCa (SHR=1.9, 95% CI 1.7 to 2.0, p< 0.001). However, this difference was no longer statistically significant when also adjusted for use of definitive therapy (SHR=1.0, 95% CI 1.0 to 1.1, p=0.3).
CONCLUSIONS: Risk-adjusted PCM is significantly higher in England compared with the USA. This difference may be explained by less frequent use of definitive therapy in England.
Sachdeva A, van der Meulen JH, Emberton M, Cathcart PJ. Are you the author?
Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK; Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, Freeman Hospital, Newcastle-upon-Tyne, UK; London School of Hygiene & Tropical Medicine, London, UK; Centre for Experimental Cancer Medicine, Bart's Cancer Institute, Queen Mary University of London, London, UK.
Reference: BMJ Open. 2015 Feb 24;5(2):e006805.